Abstract 2453
Background
Recent development in cancer care challenges the earlier and more linear care trajectory. This implies an increased need for symptom management and support. In research on intensity of care at end-of-life (EOL), there is a trend to increased utilization of health, such as re-admissions, emergency admissions and to intensive care (ICU). Previous research has investigated factors such as gender, socio-economic status, comorbidities and type of disease. Research on symptoms leading to hospitalizations reveal that more than half of symptoms were related to disease and 30% to side-effects from treatment. Some research reveals that symptom burden in hospitalized patients may be associated with hospital length of stay (LOS) and re-admissions. This study aims to analyze the relationship between Health-Related Quality of Life (HRQoL) and different aspects of health care utilization, such as; LOS, re-admissions within 30 days and unplanned care.
Methods
Survey data using the European Organization for Research and Treatment of Cancer (EORTC QLQ C30) tool on HRQoL were linked data from the Swedish Cancer Quality registries and the database for health care utilization. Patients with a complex care trajectory (in this study Gynecology, Head & Neck, Hematology and Upper GI cancer) were included. Functional scales and symptom scales from EORTC QLQ C30 were analyzed for correlations with LOS, re- admissions within 30 days and unplanned care. Independent variables are patient demographics and clinical variables such as; treatment and/or type of treatment, performance status, co-morbidities and referral to palliative care.
Results
In total, 1872 patients responded to the survey (response rate 64 %), 41 % men and 59 % women (mean age 67 years). The number of patients in each group are; Gynecological (n 598), Hematological (n 461), Head & Neck (n 395) and Upper GI cancers (n 418). Analysis are currently ongoing with multivariate regression models and will be presented in the poster/oral presentation.
Conclusions
On possible correlations between different factors related to aspects of care utilization will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This investigation and study was supported by grants from the Cancer Research Foundation in Northern Sweden.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract